Norihiro Ishii

Norihiro Ishii

Auto-generated profile, based on publicly available information

Norihiro Ishii

Division of Hepatobiliary and Pancreatic Surgery Department of General Surgical Science Gunma University Graduate School of Medicine Gunma Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
MTMariko Tsukagoshi
Mariko Tsukagoshi
KAKenichiro Araki
Kenichiro Araki
TITakamichi Igarashi
Takamichi Igarashi
NINorihiro Ishii
Norihiro Ishii
SKShunsuke Kawai
Shunsuke Kawai
KSKen Shirabe
Ken Shirabe
Increasing evidence suggests that nutritional indices, including the geriatric nutritional risk index (GNRI) and prognostic nutritional index (PNI), are predictors of poor prognosis in patients with hepatocellular carcinoma (HCC). Hence, this study aimed to explore the value of the GNRI and PNI in evaluating postoperative prognosis in patients with HCC, particularly regarding its recurrence patterns. We performed a retrospective analysis of 203 patients with HCC who underwent initial hepatic resection. Patients were divided into two groups according to the GNRI (cutoff: 98) and PNI (cutoff: 45). The GNRI and PNI were significantly associated with body composition (body mass index and skeletal muscle mass index), hepatic function (Child-Pugh Score), tumor factors (tumor size and microvascular invasion), and perioperative factors (blood loss and postoperative hospitalization). Patients with a low PNI or low GNRI had significantly worse overall survival (OS) and recurrence-free survival. Patients with early recurrence had lower PNI and GNRI scores than those without early recurrence. Patients with extrahepatic recurrence had lower PNI and GNRI scores than those without extrahepatic recurrence. The PNI and GNRI might be useful in predicting the prognosis and recurrence patterns of patients with HCC after hepatic resection.

24 October 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
NINorihiro Ishii
Norihiro Ishii
KAKenichiro Araki
Kenichiro Araki
TYTakehiko Yokobori
Takehiko Yokobori
KHKei Hagiwara
Kei Hagiwara
DGDorgormaa Gantumur
Dorgormaa Gantumur
KSKen Shirabe
Ken Shirabe
Despite recent advances in cancer treatment, pancreatic cancer is a highly malignant tumor type with a dismal prognosis and it is characterized by dense desmoplasia in the cancer tissue. Cancer‐associated fibroblasts (CAF) are responsible for this fibrotic stroma and promote cancer progression. We previously reported that a novel natural compound conophylline (CnP) extracted from the leaves of a tropical plant reduced liver and pancreatic fibrosis by suppression of stellate cells. However, there have been no studies to investigate the effects of CnP on CAF, which is the aim of this work. Here, we showed that CAF stimulated indicators of pancreatic cancer malignancy, such as proliferation, invasiveness, and chemoresistance. We also showed that CnP suppressed CAF activity and proliferation, and inhibited the stimulating effects of CAF on pancreatic cancer cells. Moreover, CnP strongly decreased the various cytokines involved in cancer progression, such as interleukin (IL)‐6, IL‐8, C‐C motif chemokine ligand 2 (CCL2), and C‐X‐C motif chemokine ligand 12 (CXCL12), secreted by CAF. In vivo, CAF promoted tumor proliferation and desmoplastic formation in a mouse xenograft model, CnP reduced desmoplasia of tumors composed of pancreatic cancer cells + CAF, and combination therapy of CnP with gemcitabine remarkably inhibited tumor proliferation. Our findings suggest that CnP is a promising therapeutic strategy of combination therapy with anticancer drugs to overcome refractory pancreatic cancers.

24 July 2019 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
NINorihiro Ishii
Norihiro Ishii
NHNorifumi Harimoto
Norifumi Harimoto
KAKenichiro Araki
Kenichiro Araki
RMRyo Muranushi
Ryo Muranushi
KHKouki Hoshino
Kouki Hoshino
KSKen Shirabe
Ken Shirabe

5 September 2023 in Hepatology Research
Verified
Journal Article
Closed access
NHNorifumi Harimoto
Norifumi Harimoto
MTMariko Tsukagoshi
Mariko Tsukagoshi
TOTakayuki Okuyama
Takayuki Okuyama
KHKouki Hoshino
Kouki Hoshino
KHKei Hagiwara
Kei Hagiwara
KSKen Shirabe
Ken Shirabe

25 April 2023 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
MTMariko Tsukagoshi
Mariko Tsukagoshi
AWAkira Watanabe
Akira Watanabe
KAKenichiro Araki
Kenichiro Araki
NINorihiro Ishii
Norihiro Ishii
KHKei Hagiwara
Kei Hagiwara
KSKen Shirabe
Ken Shirabe
Aim: This study aimed to evaluate the usefulness of the serum creatinine/cystatin C (Cr/CysC) ratio as a prognostic factor after pancreatic surgery in patients with pancreatic cancer.Methods: We retrospectively analyzed the data of 88 patients with pancreatic ductal carcinoma who underwent pancreatic surgery from January 2017 to December 2020. CysC measured from frozen serum samples and circulating Cr levels were used to calculate the Cr/CysC ratio. The cutoff value of the Cr/CysC ratio was determined using receiver operating characteristic curves. Cox proportional hazards model analysis and survival curves were applied to identify the prognostic factors.Results: The optimal cutoff value of the Cr/CysC ratio for predicting mortality after surgery was 1.05. This study included 20 (22.7%) and 68 (77.3%) patients with high and low Cr/CysC ratios, respectively. The low Cr/CysC ratio was significantly associated with female sex (p = 0.020) and higher levels of C‐reactive protein (p = 0.020). The postoperative length of stay was significantly longer in patients with low Cr/CysC rates (p = 0.044). Patients with low Cr/CysC ratio showed poorer prognosis in relapse‐free survival (hazard ratio [HR] = 3.33; 95% confidence interval [CI]: 1.54–4.20; p = 0.002) and overall survival (HR = 2.52, 95% CI: 1.04–6.10, p = 0.041), respectively, which were significantly worse than in those with high Cr/CysC ratios (p = 0.003 and 0.049, respectively).Conclusion: The Cr/CysC ratio could be a useful screening tool for predicting the prognosis of patients with pancreatic ductal carcinoma undergoing pancreatic surgery.

6 July 2022 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
KAKenichiro Araki
Kenichiro Araki
KSKei Shibuya
Kei Shibuya
NHNorifumi Harimoto
Norifumi Harimoto
AWAkira Watanabe
Akira Watanabe
MTMariko Tsukagoshi
Mariko Tsukagoshi
KSKen Shirabe
Ken Shirabe